Wipfli Financial Advisors LLC acquired a new position in Axonics, Inc. (NASDAQ:AXNX – Get Rating) in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 393 shares of the company’s stock, valued at approximately $28,000.
A number of other large investors also recently bought and sold shares of the business. Nisa Investment Advisors LLC raised its stake in Axonics by 14.1% in the second quarter. Nisa Investment Advisors LLC now owns 1,620 shares of the company’s stock worth $92,000 after buying an additional 200 shares in the last quarter. LPL Financial LLC raised its stake in Axonics by 6.3% in the second quarter. LPL Financial LLC now owns 3,727 shares of the company’s stock worth $211,000 after buying an additional 222 shares in the last quarter. Captrust Financial Advisors raised its stake in Axonics by 34.1% in the second quarter. Captrust Financial Advisors now owns 947 shares of the company’s stock worth $54,000 after buying an additional 241 shares in the last quarter. Raymond James Financial Services Advisors Inc. increased its position in shares of Axonics by 6.7% during the first quarter. Raymond James Financial Services Advisors Inc. now owns 5,207 shares of the company’s stock worth $326,000 after purchasing an additional 326 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD increased its position in shares of Axonics by 3.1% during the second quarter. Price T Rowe Associates Inc. MD now owns 10,866 shares of the company’s stock worth $616,000 after purchasing an additional 326 shares in the last quarter. Institutional investors own 97.49% of the company’s stock.
Wall Street Analyst Weigh In
A number of brokerages have recently issued reports on AXNX. Morgan Stanley reduced their price target on Axonics from $92.00 to $76.00 and set an “overweight” rating on the stock in a research report on Friday, January 6th. TheStreet raised Axonics from a “d+” rating to a “c” rating in a research report on Monday, October 31st. Truist Financial reduced their price target on Axonics from $90.00 to $82.00 and set a “buy” rating on the stock in a research report on Tuesday, December 20th. Royal Bank of Canada started coverage on Axonics in a research report on Friday, October 21st. They set an “outperform” rating and a $85.00 price target on the stock. Finally, Piper Sandler boosted their price objective on shares of Axonics from $82.00 to $84.00 and gave the company an “overweight” rating in a report on Wednesday, October 5th. Two research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat, Axonics currently has an average rating of “Moderate Buy” and a consensus target price of $78.11.
Insider Buying and Selling at Axonics
Axonics Stock Performance
NASDAQ:AXNX opened at $62.02 on Friday. Axonics, Inc. has a one year low of $38.41 and a one year high of $79.92. The firm has a market cap of $3.07 billion, a price-to-earnings ratio of -37.59 and a beta of 0.43. The firm’s fifty day moving average is $63.46 and its two-hundred day moving average is $67.07.
Axonics (NASDAQ:AXNX – Get Rating) last posted its quarterly earnings results on Monday, October 31st. The company reported ($0.34) EPS for the quarter, beating the consensus estimate of ($0.47) by $0.13. Axonics had a negative net margin of 31.35% and a negative return on equity of 15.63%. The company had revenue of $70.38 million for the quarter, compared to analyst estimates of $62.98 million. During the same period in the prior year, the company earned ($0.38) earnings per share. The firm’s revenue was up 50.0% on a year-over-year basis. As a group, equities research analysts predict that Axonics, Inc. will post -1.59 earnings per share for the current fiscal year.
Axonics, Inc is a medical device company, which engages in developing and commercializing of novel implantable sacral neuromodulation (SNM) devices to treat patients with bladder and bowel dysfunction. Its product Bulkamid, which is a urethral bulking agent used to treat stress urinary incontinence in women.
- Get a free copy of the StockNews.com research report on Axonics (AXNX)
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving ’23 Growth
- Is Airbnb Setting Up To Rally 38%, As Analysts Are Forecasting?
- Does a Price Cut for Tesla Vehicles Mean the Same for TSLA Stock?
- Microsoft Layoffs Signal Layoffs for Other Tech Companies?
Receive News & Ratings for Axonics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axonics and related companies with MarketBeat.com's FREE daily email newsletter.